Multi-organ proteomic clock
Biomarker1 paper1 finding
- Human trial1
Interventions
1Semaglutide
downin humans1−5.2%Moderate certainty
1 study
Semaglutide
downin humans1−5.2%Moderate certainty
Semaglutide decreases multi-organ proteomic clock in humans (5.2%).
Human trialin SELECT trial participants2.4 mg
Semaglutide Reduces Multiorgan Proteomic-Based Biological Age across Cohorts · ADA Scientific Sessions 2026 abstract · 5 Jun 2026
Latest
1ADA Scientific Sessions 2026 AbstractHuman trial